Brief: Genetron Health Receives CE Mark For 8-Gene Lung Cancer Assay
13/07/2021 14:46
July 13 (Reuters) - Genetron Holdings Ltd GTH.O :
* GENETRON HEALTH RECEIVES CE MARK FOR 8-GENE LUNG CANCER
ASSAY
AND PROVIDES FDA REFERENCE PANEL COMPARATIVE DATA OF ITS
SARS-COV-2 RNA TEST
Source text for Eikon: ID:nGNX71D4lW
Further company coverage: GTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genetron Holdings
See all newsBrief: Genetron Holdings Requested That Trading Of Its ADSs On Nasdaq Be Suspended As Of Close Of Trading On March 28, 2024
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius
U.S. STOCKS ON THE MOVE-Scholar Rock, Target, LL Flooring
U.S. STOCKS ON THE MOVE-First Solar, Genetron, Viasat
Genetron surges on $126 mln deal to go private